The Effect of Recombinant Human Growth Hormone with or without Rosiglitazone on Hepatic Fat Content in HIV-1-Infected Individuals: A Randomized Clinical Trial

Abstract

Background

Hepatic fat is related to insulin resistance (IR) and visceral adipose tissue (VAT) in HIV+ and uninfected individuals. Growth hormone (GH) reduces VAT but increases IR. We evaluated the effects of recombinant human GH (rhGH) and rosiglitazone (Rosi) on hepatic fat in a substudy of a randomized controlled trial.

Methods

HIV+ subjects with abdominal obesity and IR (QUICKI≤0.33) were randomized to rhGH 3 mg daily, Rosi 4 mg twice daily, the combination or double placebo. Hepatic fat was measured by magnetic resonance spectroscopy, visceral fat by MRI and IR by frequently sampled intravenous glucose tolerance tests at baseline and week 12.

Results

31 subjects were studied at both time points. Significant correlations between hepatic fat and VAT (r=0.41; P=0.02) and QUICKI (r=0.39; P<0.05) were seen at baseline. IR rose with rhGH but not Rosi. When rhGH treatment groups were combined, hepatic fat expressed as percentage change decreased significantly (P<0.05) but did not change in Rosi (P=0.71). There were no correlations between changes in hepatic fat and VAT (P=0.4) or QUICKI (P=0.6). In a substudy of 21 subjects, a trend was noticed between changes in hepatic fat and serum insulin-like growth factor-1 (IGF-1; P=0.09).

Conclusions

Hepatic fat correlates significantly with both VAT and IR, but changes in hepatic fat do not correlate with changes in VAT and glucose metabolism. Hepatic fat content is reduced by rhGH but Rosi has no effect. These results suggest an independent effect of GH or IGF-1 on hepatic fat. The study was registered at Clinicaltrials.gov (NCT00130286).

References

Farrell

G.C.

, Larter

C.Z.

Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Hepatology 2006; 43 Suppl 1: S99–S112.

Brea

, Mosquera

, Martin

Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study.

Arterioscler Thromb Vasc Biol 2005; 25: 1045–1050.

Villanova

, Moscatiello

, Ramilli

Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease.

Hepatology 2005; 42: 473–480.

Seppälä-Lindroos

, Vehkavaara

, Häkkinen

A.M.

Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

J Clin Endocrinol Metab 2002; 87: 3023–3028.

Cappell

M.S.

Hepatobiliary manifestation of the acquired immune deficiency syndrome.

Am J Gastroenterol 1991; 86: 1–15.

Sutinen

, Hakkinen

A.M.

, Westerbacka

Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy.

AIDS 2002; 16: 2183–2193.

Grinspoon

, Carr

Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

N Engl J Med 2005; 352: 48–62.

Carr

, Samaras

, Burton

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

AIDS 1998; 12: F51–F58.

Attanasio

A.F.

, Mo

, Erfurth

E.M.

Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement.

J Clin Endocrinol Metab 2010; 95: 74–81.

10.

Adams

L.A.

, Feldstein

, Lindor

K.D.

Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction.

Hepatology 2004; 39: 909–914.

11.

Hong

J.W.

, Kim

J.Y.

, Kim

Y.E.

, Lee

E.J.

Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men.

Horm Metab Res 2011; 43: 48–54.

12.

Miller

K.K.

, Biller

B.M.

, Lipman

J.G.

Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk.

J Clin Endocrinol Metab 2005; 90: 768–774.

13.

Rietschel

, Hadigan

, Corcoran

Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.

J Clin Endocrinol Metab 2001; 86: 504–510.

14.

Franco

, Brandberg

, Lonn

Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.

J Clin Endocrinol Metab 2005; 90: 1466–1474.

15.

Johannsson

, Marin

, Lonn

Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.

J Clin Endocrinol Metab 1997; 82: 727–734.

16.

Takahashi

, Iida

, Takahashi

Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency.

Gastroenterology 2007; 132: 938–943.

17.

Engelson

E.S.

, Glesby

M.J.

, Mendez

Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.

J Acquir Immune Defic Syndr 2002; 30: 379–391.

18.

Miyazaki

, Glass

, Triplitt

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients.

Diabetologia 2001; 44: 2210–2219.

19.

Gelato

M.C.

, Mynarcik

D.C.

, Quick

J.L.

Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.

J Acquir Immune Defic Syndr 2002; 31: 163–170.

20.

Glesby

M.J.

, Albu

, Chiu

Y.L.

Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.

PLoS ONE 2013; 8: e61160.

21.

Katz

, Nambi

S.S.

, Mather

Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

J Clin Endocrinol Metab 2000; 85: 2402–2410.

22.

, Ionescu

, Glesby

M.J.

, Kotler

D.P.

, Engelson

E.S.

Insulin resistance, hepatic lipid and adipose tissue distribution in HIV infected men.

Antivir Ther 2008; 13: 423–428.

23.

Szczepaniak

L.S.

, Babcock

E.E.

, Schick

Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo.

Am J Physiol 1999; 276: E977–E989.

24.

Engelson

E.S.

, Kotler

D.P.

, Tan

, Wang

, Pierson

R.N.

, Heymsfield

S.B.

Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging.

Am J Clin Nutr 1999; 69: 1162–1169.

25.

Lohman

T.G.

Dual energy x-ray absorptiometry. In Human body composition, Roche

A.F.

, Heymsfield

S.B.

, and Lohman

T.G.

(editors). Champaign, IL: Human Kinetics, 1996, p. 63–78.

26.

Steil

G.M.

, Murray

, Bergman

R.N.

, Buchanan

T.A.

Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design.

Diabetes 1994; 43: 1365–1371.

27.

Boston

R.C.

, Stefanovski

, Moate

P.J.

MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test.

Diabetes Technol Ther 2003; 5: 1003–1015.

28.

Ryysy

, Häkkinen

A.M.

, Goto

Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.

Diabetes 2000; 49: 749–758.

29.

Stanley

T.L.

, Feldpausch

M.N.

, Oh

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

JAMA 2014; 312: 380–389.

30.

Khovidhunkit

, Kim

M.S.

, Memon

R.A.

Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.

J Lipid Res 2004; 45: 1169–1196.

31.

Runchey

S.S.

, Boyko

E.J.

, Ioannou

G.N.

, Utzschneider

K.M.

Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States.

J Gastroenterol Hepatol 2014; 29: 589–596.

32.

Schwarz

J.M.

, Mulligan

, Lee

Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV infected patients with fat accumulation.

J Clin Endocrinol Metab 2002; 87: 942.

33.

Hadigan

, Borgonha

, Rabe

, Young

, Grinspoon

Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy.

Metabolism 2002; 51: 1143–1147.

34.

D'Amico

, Shi

, Sekhar

R.V.

Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome.

Am J Clin Nutr 2006; 84: 204–211.

35.

Segerlantz

, Bramnert

, Manhem

Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.

Eur J Endocrinol 2003; 149: 511–519.

36.

Mayerson

A.B.

, Hundal

R.S.

, Dufour

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.

Diabetes 2002; 51: 797–802.

37.

Sutinen

, Hakkinen

A.M.

, Westerbacka

Rosiglitazone in the treatment of HAART-associated lipodystrophy – a randomized double-blind placebo-controlled study.

Antivir Ther 2003; 8: 199–207.

38.

Gore

D.C.

, Honeycutt

, Jahoor

Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients.

Arch Surg 1991; 126: 38–43.

39.

Schambelan

, Mulligan

, Grunfeld

Recombinant human growth hormone in patients with HIV-associated wasting.

Ann Intern Med 1996; 125: 873–882.

40.

Kotler

D.P.

, Muurahainen

, Grunfeld

Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients.

J Acquir Immune Defic Syndr 2004; 35: 239–252.

41.

Grunfeld

, Thompson

, Brown

S.J.

Recombinant human growth hormone (r-hGH) to treat HIV-associated adipose redistribution syndrome (HARS): 12-week induction and 24-week maintenance therapy.

J Acquir Immune Defic Syndr 2007; 45: 286–297.

42.

J.C.

, Mulligan

, Noor

M.A.

The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.

J Clin Endocrinol Metab 2001; 86: 3480–3487.

43.

Miyazaki

, Glass

, Triplitt

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients.

Diabetologia 2001; 44: 2210–2219.

44.

Mori

, Murakawa

, Okada

Effect of troglitazone on body fat distribution in type 2 diabetic patients.

Diabetes Care 1999; 22: 908–912.

45.

Smith

S.R.

, de Jonge

, Volaufova

Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.

Metabolism 2005; 54: 24–32.

46.

Hadigan

, Yawetz

, Thomas

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.

Ann Intern Med 2004; 140: 786–794.

47.

Feldt

, Oette

, Kroidl

Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome.

Infection 2006; 34: 55–61.

48.

Carr

, Workman

, Carey

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

Lancet 2004; 363: 429–438.

49.

Gavrila

, Hsu

, Tsiodras

Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

Clin Infect Dis 2005; 40: 745–749.

50.

Tungsiripat

, Bejjani

D.E.

, Rizk

Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens.

AIDS 2010; 24: 1291–1298.

51.

Yki-Järvinen

Thiazolidines and the liver in humans.

Curr Opin Lipidol 2009; 20: 477–483.

52.

Macallan

D.C.

, Baldwin

, Mandalia

Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone.

HIV Clin Trials 2008; 9: 254–268.

53.

Falutz

, Allas

, Kotler

A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

AIDS 2005; 19: 1279–1287.

54.

Falutz

, Allas

, Blot

Metabolic effects of a growth hormone-releasing factor in patients with HIV.

N Engl J Med 2007; 357: 2359–2370.

55.

Nissen

S.E.

, Wolski

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

N Engl J Med 2007; 356: 2457–2471.

56.

Singh

, Loke

Y.K.

, Furberg

C.D.

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

JAMA 2007; 298: 1189–1195.